4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents
- 1 April 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 63 (16), 1617-1625
- https://doi.org/10.1016/j.jacc.2013.12.036
Abstract
No abstract availableKeywords
Funding Information
- Cordis
- Medtronic
- St. Jude Medical
- Eli Lilly and Company
- AstraZeneca
- Edwards Lifesciences
This publication has 16 references indexed in Scilit:
- Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: 2-Year Follow-Up of the Randomized TWENTE TrialJournal of the American College of Cardiology, 2013
- Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary StentsCirculation, 2012
- Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary StentsCirculation, 2012
- Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trialThe Lancet, 2011
- A Prospective Natural-History Study of Coronary AtherosclerosisThe New England Journal of Medicine, 2011
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsThe New England Journal of Medicine, 2010
- Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificityEuroIntervention, 2010
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting StentsCirculation, 2006
- Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex PatientsCirculation, 2004